350-19-6

Basic information

• Product Name: ETHYL 3,5-DIFLUOROBENZOATE
• Synonyms: ETHYL 3,5-DIFLUOROBENZOATE;RARECHEM AL BI 0216
• CAS NO: 350-19-6
• Molecular Formula: C₉H₈F₂O₂
• Molecular Weight: 186.16
• Mol File: 350-19-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 3,5-DIFLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3,5-DIFLUOROBENZOATE(350-19-6)
• EPA Substance Registry System: ETHYL 3,5-DIFLUOROBENZOATE(350-19-6)

Safety Data

• Hazardous Substances Data: 350-19-6(Hazardous Substances Data)

Usage

General Description

ETHYL 3,5-DIFLUOROBENZOATE is a chemical compound that belongs to the class of esters. It is synthesized by the reaction of ethyl alcohol with 3,5-difluorobenzoic acid. ETHYL 3,5-DIFLUOROBENZOATE is commonly used in the manufacturing of pharmaceuticals, particularly in the production of antifungal agents and anti-inflammatory drugs. It is also utilized in organic synthesis as a building block for the creation of various functionalized molecules. ETHYL 3,5-DIFLUOROBENZOATE is a colorless liquid with a fruity odor and is considered to be moderately hazardous, as it can cause irritation to the skin, eyes, and respiratory system upon exposure. Proper safety measures must be taken when handling and working with this chemical.

Upstream product

• 64-17-5 ethanol 
• 455-40-3 3,5-difluorobenzoic acid 
• 64248-63-1 3,5-difluorobenzonitrile 
• 1949-51-5 3,5-diaminobenzoic acid ethyl ester 

Downstream Products

• 1384448-23-0 (3,5-difluorophenyl)methan-d2-ol-d 
• 455-40-3 3,5-difluorobenzoic acid 
• 295311-40-9 3-fluoro-5-(4-morpholinyl)benzoic acid 
• 884340-51-6 3-fluoro-5-morpholinobenzoyl chloride 
• 1562995-71-4 ethyl 3,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 842140-51-6 3-(3,5-difluorophenyl)-3-oxopropanenitrile 

Relevant articles and documents

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold

Tropomyosin receptor kinase (TRK) is an ideal target for treating cancers caused by the NTRK gene fusion. In this study, more than 60 2,4-diaminopyrimidine derivatives were prepared to understand the structure-activity relationship and confirm the rationality of the pharmacophore model reported previously. Among them, compound 19k was found to be a potent pan-TRK inhibitor that inhibits the proliferation of Km-12 cell lines. Additionally, compound 19k induced the apoptosis of Km-12 cells in a concentration-dependent manner. Western blot analysis revealed that compound 19k inhibited the phosphorylation of TRK to block downstream pathways. Compound 19k also possessed outstanding plasma stability and liver microsomal stability in vitro, with half-lives greater than 289.1 min and 145 min, respectively. Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17.4%. These results demonstrate that compound 19k could serve as a novel lead compound for overcoming NTRK-fusion cancers.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.

5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS

The invention provides compounds of the formula (I) or a salt, solvate or N-oxide thereof, wherein:R1 and R2 are the same or different and each is selected from hydrogen, saturated C1-3 hydrocarbyl, halogen and cyano; X is